Press releases

17th February 2020

Analysis of RNA sequences and modifications by mass spectrometry published in Nature Communications

STORM Principal Scientists and collaborators develop novel algorithm for measuring RNA modifications by mass spectrometry

9th December 2019

STORM Therapeutics’ collaborator awarded ASH–BSH Abstract Achievement Award at the 61st ASH Annual Meeting & Exposition

Konstantinos Tzelepis, PhD, presented award-winning abstract on METTL3

18th September 2019

STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes

Data to be presented at inaugural STORM Therapeutics RNA Epigenetics in Human Disease Conference in Cambridge, UK

20th August 2019

STORM Therapeutics to Host First RNA Epigenetics Conference in Cambridge UK

STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapeutics modulating RNA epigenetics, today announced that it will be hosting an international conference focused on the emerging field of “RNA epigenetics”.

27th June 2019

STORM Therapeutics appoints Dr John Haurum to the Board of Directors

STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.